This company has been acquired
LogicBio Therapeutics Management
Management criteria checks 1/4
Key information
Fred Chereau
Chief executive officer
US$2.2m
Total compensation
| CEO salary percentage | 24.3% |
| CEO tenure | 6.6yrs |
| CEO ownership | 0.8% |
| Management average tenure | 1.8yrs |
| Board average tenure | 3.4yrs |
Recent management updates
Recent updates
LogicBio jumps 648% on buyout deal with AstraZeneca unit Alexion
Oct 03Bullish: Analysts Just Made A Notable Upgrade To Their LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Forecasts
Aug 20
LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 18LogicBio GAAP EPS of -$0.15, revenue of $3.2M
Aug 15Is LogicBio Therapeutics (NASDAQ:LOGC) Weighed On By Its Debt Load?
Jan 11Does LogicBio Therapeutics (NASDAQ:LOGC) Have A Healthy Balance Sheet?
Aug 18LogicBio EPS misses by $0.06, beats on revenue
May 10LogicBio announces agreements with CANbridge Pharma and Daiichi Sankyo
Apr 27Is LogicBio Therapeutics (NASDAQ:LOGC) Using Debt Sensibly?
Apr 12Is LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Popular Amongst Insiders?
Mar 08The LogicBio Therapeutics (NASDAQ:LOGC) Share Price Has Gained 12% And Shareholders Are Hoping For More
Jan 15LogicBio extends collaboration with Children's Medical Research Institute
Jan 07LogicBio Therapeutics names new CFO
Dec 22Looking In On LogicBio
Nov 17LogicBio reports Q3 results
Nov 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2022 | n/a | n/a | -US$27m |
| Jun 30 2022 | n/a | n/a | -US$31m |
| Mar 31 2022 | n/a | n/a | -US$36m |
| Dec 31 2021 | US$2m | US$543k | -US$40m |
| Sep 30 2021 | n/a | n/a | -US$38m |
| Jun 30 2021 | n/a | n/a | -US$36m |
| Mar 31 2021 | n/a | n/a | -US$33m |
| Dec 31 2020 | US$2m | US$479k | -US$33m |
| Sep 30 2020 | n/a | n/a | -US$37m |
| Jun 30 2020 | n/a | n/a | -US$40m |
| Mar 31 2020 | n/a | n/a | -US$42m |
| Dec 31 2019 | US$633k | US$510k | -US$40m |
| Sep 30 2019 | n/a | n/a | -US$32m |
| Jun 30 2019 | n/a | n/a | -US$29m |
| Mar 31 2019 | n/a | n/a | -US$23m |
| Dec 31 2018 | US$2m | US$411k | -US$18m |
| Sep 30 2018 | n/a | n/a | -US$18m |
| Jun 30 2018 | n/a | n/a | -US$11m |
| Mar 31 2018 | n/a | n/a | -US$9m |
| Dec 31 2017 | US$779k | US$385k | -US$8m |
Compensation vs Market: Fred's total compensation ($USD2.23M) is above average for companies of similar size in the US market ($USD750.11K).
Compensation vs Earnings: Fred's compensation has increased whilst the company is unprofitable.
CEO
Fred Chereau (55 yo)
6.6yrs
Tenure
US$2,228,208
Compensation
Mr. Frederic Chereau, M.B.A., also known as Fred, is the Chairman of the Board of Coave Therapeutics since October 2022 and has been its Independent Non-Executive Director since October 2021. He has execut...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.6yrs | US$2.23m | 0.77% $ 525.4k | |
| Co-Founder | no data | US$156.64k | 2.38% $ 1.6m | |
| Chief Medical Officer | 2.4yrs | US$1.54m | 0.010% $ 6.9k | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Co-Founder | 8.3yrs | no data | no data | |
| Interim CFO | less than a year | no data | no data | |
| Global VP & Head of Technology Development | 3.6yrs | no data | no data | |
| Chief Scientific Officer | 2yrs | US$1.34m | no data | |
| General Counsel & Corporate Secretary | 1.5yrs | no data | no data | |
| VP & Head of Human Resources | 1.2yrs | no data | no data | |
| Senior Vice President of Strategy & Portfolio Management | 1.4yrs | no data | no data | |
| Chief Business Officer | 1.3yrs | no data | no data |
1.8yrs
Average Tenure
55yo
Average Age
Experienced Management: LOGC's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | no data | US$2.23m | 0.77% $ 525.4k | |
| Co-Founder | 6.8yrs | US$156.64k | 2.38% $ 1.6m | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4.2yrs | US$87.39k | 0.0095% $ 6.5k | |
| Independent Chairman of the Board | 4.1yrs | US$113.64k | 0.012% $ 8.1k | |
| Independent Director | 2.7yrs | US$82.02k | 0.0089% $ 6.0k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 6.8yrs | US$81.14k | 0.068% $ 46.2k | |
| Independent Director | 1.9yrs | US$76.77k | 0% $ 0 | |
| Independent Director | 1.9yrs | US$79.64k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | less than a year | US$40.31k | no data |
3.4yrs
Average Tenure
58yo
Average Age
Experienced Board: LOGC's board of directors are considered experienced (3.4 years average tenure).